💊Aurobindo Pharma Strengthens CRDMO Business with A1 Biochem Acquisition

Aurobindo Pharma Ltd. has announced that its wholly owned subsidiary, **Apitoria Pharma Pvt. Ltd.**, will acquire an **80% stake** in the Contract Research Organization (CRO) business of **A1 Biochem Group** for an **enterprise value of USD 17 million** 💰 on a debt-free and cash-free basis. As part of the transaction, A1 Biochem Labs (India) Pvt. Ltd. will also acquire **100% ownership of A1 Biochem Labs LLC, USA**, along with the CRO business of A1 Biochem Research (India) Pvt. Ltd. The existing promoter will retain a **20% stake** and continue to lead the business. 🤝 The acquisition is aimed at expanding Aurobindo's presence beyond API manufacturing by creating an integrated **Contract Research, Development and Manufacturing Organization (CRDMO)** platform. 🧪 The deal adds an established CRO business with **50+ global clients, over 800 completed projects, and more than 90 scientists** operating from laboratories in **Hyderabad, India, and Wilmington, USA**. 🌍 For FY26, A1 Biochem Group reported **revenue of ₹102.44 crore** and **EBITDA of ₹46.55 crore**. 📈 The transaction is expected to be completed within **90–120 days**, subject to customary regulatory approvals. ✅ ⚠️ **Disclaimer:** This article is for informational purposes only and should not be considered investment advice. $AUROPHARMA